Merck & Co., Inc. $MRK Stock Purchased by Sanders Morris Harris LLC

Sanders Morris Harris LLC raised its holdings in Merck & Co., Inc. (NYSE:MRK) by 399.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 7,874 shares of the company’s stock after acquiring an additional 6,296 shares during the period. Sanders Morris Harris LLC’s holdings in Merck & Co., Inc. were worth $1,157,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in MRK. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Bullseye Investment Management LLC acquired a new position in Merck & Co., Inc. in the second quarter valued at $27,000. Horizons Wealth Management acquired a new position in Merck & Co., Inc. in the third quarter valued at $30,000. Graney & King LLC increased its stake in Merck & Co., Inc. by 400.0% in the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC purchased a new position in Merck & Co., Inc. during the second quarter worth about $41,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 3.9%

Shares of NYSE MRK traded up $5.49 during trading on Wednesday, hitting $147.47. 9,795,556 shares of the company traded hands, compared to its average volume of 10,626,400. The firm has a market capitalization of $363.83 billion, a P/E ratio of 117.97, a P/E/G ratio of 6.72 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a 50-day moving average price of $144.91 and a 200-day moving average price of $128.93. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were paid a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda could support upcoming results: Analysts expect continued Keytruda sales growth, contributions from earlier-stage launches and expanded indications to help Merck’s third-quarter revenue and earnings. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Potentially faster cancer-vaccine manufacturing: CEO Rob Davis said the personalized cancer vaccine being developed with Moderna should become faster to manufacture over time. He described the current process as complex but increasingly standardized, which could improve the program’s commercial scalability. Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
• Positive Sentiment: Pipeline visibility improved: Merck will present first-time Phase 3 results from three pivotal oncology trials and more than 90 additional abstracts at the upcoming ESMO 2026 conference. Positive data could strengthen confidence in products that may eventually help offset Keytruda’s patent and competitive pressures. Merck Showcases First-Time Pivotal Phase 3 Results
• Positive Sentiment: Analyst endorsement: Leerink Partners initiated or reiterated a Buy rating, adding support to the positive near-term sentiment around Merck’s earnings outlook and oncology pipeline. Merck Gets a Buy from Leerink Partners
• Neutral Sentiment: Board appointment: Merck elected Paul J. Diaz to its board of directors. The move adds leadership and healthcare-sector experience but is unlikely to materially change near-term earnings expectations. Paul J. Diaz Elected to Merck Board
• Negative Sentiment: Longer-term Keytruda risk: Biosimilar competition is expected to emerge in 2028–2029, creating a significant future threat to Merck’s largest product and increasing the importance of successful pipeline launches.
• Negative Sentiment: Some earnings estimates were reduced: Erste Group lowered its FY2026 EPS estimate to $2.73 from $2.75 and its FY2027 estimate to $9.47 from $9.52, signaling modest pressure on forecasts. Merck analyst estimates

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MRK. Berenberg Bank raised their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Rothschild & Co Redburn lifted their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 6th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research note on Wednesday, August 12th. Sanford C. Bernstein increased their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Seventeen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Insider Activity at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard Deluca sold 11,699 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the sale, the executive vice president owned 110,167 shares of the company’s stock, valued at $14,501,282.21. The trade was a 9.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last three months. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.